Adherence to Disease-Modifying Therapies for Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Oral Disease-Modifying Therapies for Multiple Sclerosis
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drug...
متن کاملNon-adherence to Disease-Modifying Treatments in Patients with Multiple Sclerosis
Background: Multiple Sclerosis (MS) is a debilitating disease of the central nervous system. Usually, long-term MS medications are injected intramuscularly or subcutaneously, making them intolerable for many MS patients. Objectives: In the present study, the rate and the causes of non-adherence to MS disease-modifying drugs (DMDs) were assessed in patients with MS. Materials and Methods: Two ...
متن کاملPsychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
OBJECTIVES Our aim was to identify the impact of psychosocial predictors, specifically relationship style, depressive symptoms, anxiety symptoms, cognitive impairment, and culture-specific disease beliefs, on treatment adherence for multiple sclerosis (MS) patients. METHODS In this cross-sectional observational study, patients from two MS clinics in Saudi Arabia completed self-reported questi...
متن کاملAdherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis.
GA 40 mg TIW cohort: patients with GA 40 mg on their index dates or who switched to GA 40 mg during post-index and had ≥90 days of post-index after switch; for switchers, the date of the switch to GA 40 mg became the new index date n=232 Oral DMT cohort: patients whose index DMTs were ngolimod, teri unomide, or dimethyl fumarate and who did not switch to GA 40 mg TIW during post-index n=1,547 F...
متن کاملMultiple sclerosis and disease-modifying therapies.
Mia T. Minen, MD Steven Karceski, MD Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (DMTs) have been developed. These therapies are designed to decrease the number of MS attacks, and to slow the progression of the disease. They have become a standard part of the current treatment for MS. There are different classes of the currently available DM...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Managed Care & Specialty Pharmacy
سال: 2016
ISSN: 2376-0540,2376-1032
DOI: 10.18553/jmcp.2016.22.12.1394